Want to see PHGE full AI Analyst Report?
PHGE Stock Chart & Stats
$1.84
-$0.09(-11.33%)
At close: 4:00 PM EST
$1.84
-$0.09(-11.33%)
Day’s Range― - ―
52-Week Range$0.30 - $14.71
Previous CloseN/A
Volume30.96K
Average Volume (3M)1.32M
Market Cap
$3.76M
Enterprise Value-$291.54K
Total Cash (Recent Filing)$1.17M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.30
Shares Outstanding11,797,449
10 Day Avg. Volume1,108,900
30 Day Avg. Volume1,322,820
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-100.26
Price to Sales (P/S)0.00
P/FCF Ratio-4.95
Enterprise Value/Market Cap-0.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.11
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.85
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Enrollment Progress In EuropeEnrollment in European sites continues ahead of plan, supporting patient recruitment momentum while the U.S. study is on hold.
Regulatory Support And Commercial Opportunity For BX011Positive FDA feedback and guidance support advancing BX011 into a Phase 2a study for diabetic foot infections, offering access to a larger patient population and greater commercial potential.
Trial Continuity And Safety OversightIndependent data monitoring committee recommended continuation of the BX004 cystic fibrosis study with protocol amendments, indicating oversight confidence in managing observed adverse events.
Bears Say
Delayed Top-line Data Increasing Financing RiskPostponement of expected cystic fibrosis topline data pushes results later and amplifies the company's financing risk.
Financing And Liquidity RiskSecuring additional financing is a stated priority, reflecting potential liquidity constraints that could affect program advancement.
Regulatory Hold Due To Device ScrutinyFDA inquiries about a third-party nebulizer have placed the U.S. cystic fibrosis study on hold, creating regulatory uncertainty about trial continuation.
BiomX News
PHGE FAQ
What was BiomX’s price range in the past 12 months?
BiomX lowest stock price was $0.30 and its highest was $14.71 in the past 12 months.
What is BiomX’s market cap?
BiomX’s market cap is $3.76M.
When is BiomX’s upcoming earnings report date?
BiomX’s upcoming earnings report date is Aug 13, 2026 which is in 40 days.
How were BiomX’s earnings last quarter?
BiomX released its earnings results on May 14, 2026. The company reported -$7.383 earnings per share for the quarter, missing the consensus estimate of N/A by -$7.383.
Is BiomX overvalued?
According to Wall Street analysts BiomX’s price is currently Overvalued.
Does BiomX pay dividends?
BiomX does not currently pay dividends.
What is BiomX’s EPS estimate?
BiomX’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BiomX have?
BiomX has 11,797,449 shares outstanding.
What happened to BiomX’s price movement after its last earnings report?
BiomX reported an EPS of -$7.383 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.56%.
Which hedge fund is a major shareholder of BiomX?
Currently, no hedge funds are holding shares in PHGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BiomX
Operating as a holding company, BiomX Inc. is dedicated to advancing technologies within the realms of defense, security, and essential infrastructure. Its diverse array of offerings features specialized solutions like counter-unmanned aerial vehicle systems, intelligent AI-powered command-and-control, comprehensive border and perimeter protection, expansive surveillance capabilities, and aerial fire suppression tools. The firm caters to a broad spectrum of clients, encompassing national defense organizations, primary government contractors, transportation management entities, local municipalities, and key infrastructure operators. BiomX Inc. commenced operations in 2015 and maintains its principal office in Dover, Delaware.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---